Redwood AI Appoints Public Safety and Defense Advisor

Vancouver, Canada — May 5, 2026 — Leads & Copy — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N, WKN: A422EZ) has appointed Dr. Matthew A. Roberts as Public Safety and Defense Advisor. The company is also extending its investor relations program.

Redwood AI is advancing the strategic positioning of its AI-powered chemical synthesis platform, Reactosphere, across a broader range of potential applications, including public safety, biosecurity, health security, and certain defense-related areas. The company is strengthening its advisory bench with leaders whose experience spans science, innovation, and technology development to address complex societal and operational challenges.

Dr. Roberts' 25-year career includes senior executive roles at Nestlé, Abbott, Pharmavite, and Niagen Bioscience. His experience includes establishing a corporate venture fund at Nestlé focused on health innovation, co-leading at Abbott a public-private partnership with the University of Illinois that helped create the Center for Nutrition, Learning, and Memory, and expanding external research efforts at Niagen Bioscience, formerly ChromaDex, in support of peer-reviewed publications, regulatory progress, and new business areas focused on mitochondrial health. He also advises emerging companies and nonprofit organizations and has contributed to peer-reviewed work relating to scientific and technological innovation in human health.

Dr. Roberts holds a Ph.D. in Toxicology from Cornell University, an MBA from Washington University in St. Louis, and a B.Sc. in Molecular Biology from Purdue University.

In his role, Dr. Roberts will provide strategic business and technical guidance to Redwood on the application of its artificial intelligence platform to complex challenges at the intersection of public health and public safety. His work focuses on translating advanced chemistry and AI capabilities into operational systems that support frontline professionals across law enforcement, healthcare, and regulatory decision-making.

Dr. Roberts currently serves as Managing Director of Aidos Innovations, a nonprofit translational science institute developed in collaboration with the University of British Columbia and the IMAPP research program at Vancouver General Hospital. Aidos is focused on advancing technologies that bridge clinical insight, scientific innovation, and system-level implementation in response to the evolving opioid crisis and related public health challenges. Dr. Roberts brings experience in developing and operationalizing platforms such as Track & Trace, an integrated chemical intelligence system combining advanced analytical chemistry, data infrastructure, and cross-sector collaboration to generate actionable insights on illicit drug supply and its impact on communities.

Redwood AI has also extended its engagement with MCS Market Communication Service GmbH to provide market awareness and corporate communications services, including through content creation, project management, third-party media distribution, and digital market awareness initiatives. The company will pay a cash fee of CAD $900,000 for the services, which are scheduled to run until July 30, 2026, or budget exhaustion. The agreement may be shortened or extended at the company's discretion. No securities have been provided to MCS or its principals as compensation.

Redwood AI uses artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications.

Louis Dron is the Chief Executive Officer of Redwood AI Corp.

Source: Redwood AI Corp.